BR0008966A - Sequência vbeta-dbeta-jbeta de receptor de célula t e processos para a detecção da mesma - Google Patents

Sequência vbeta-dbeta-jbeta de receptor de célula t e processos para a detecção da mesma

Info

Publication number
BR0008966A
BR0008966A BR0008966-4A BR0008966A BR0008966A BR 0008966 A BR0008966 A BR 0008966A BR 0008966 A BR0008966 A BR 0008966A BR 0008966 A BR0008966 A BR 0008966A
Authority
BR
Brazil
Prior art keywords
sequence
oligonucleotide
processes
detection
jbeta
Prior art date
Application number
BR0008966-4A
Other languages
English (en)
Inventor
Jingwu Z Zhang
Original Assignee
Baylor College Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College Medicine filed Critical Baylor College Medicine
Publication of BR0008966A publication Critical patent/BR0008966A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)

Abstract

"SEQUêNCIA VBETA-DBETA-JBETA DE RECEPTOR DE CéLULA T E PROCESSOS PARA A DETECçãO DA MESMA". Em uma modalidade, a presente invenção é direcionada a um primeiro oligonucleotídeo que compreende a seq³ência de ou derivada de 5'-CTAGGGCGGGCGGGACTCACCTAC-3' ou da seq³ência do ácido nucléico complementar à mesma. O primeiro oligonucleotídeo pode ser utilizado com um ácido nucléico entre 15 e 30 nucleotídeos que não compreende a seq³ência do primeiro oligonucleotídeo e é encontrada na região de V<225> a J<225> do gene V<225>13,1, em células T V<225>13,1, em que as seq³ências do oligonucleotídeo e o ácido nucléico não são encontrados no mesmo filamento do par do gene V<225>13,1, para amplificar uma parte do gene V<225>13,1. Alternativamente, o primeiro oligonucleotídeo pode ser utilizado com uma porção de marcação nos processos de detecção de um motivo LGRAGLTY encontrado nos receptores de células T de células T V<225>13,1. Este motivo está associado com doenças auto-imunes, tal como a esclerose múltipla (MS). Uma vez que o motivo é detectado, a doença auto-imune pode ser tratada ou seu progresso monitorado. A doença auto-imune pode ser tratada pela administração de um peptídeo que compreende o motivo LGRAGLTY.
BR0008966-4A 1999-02-23 2000-02-22 Sequência vbeta-dbeta-jbeta de receptor de célula t e processos para a detecção da mesma BR0008966A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12131199P 1999-02-23 1999-02-23
PCT/US2000/040006 WO2000050641A1 (en) 1999-02-23 2000-02-22 T CELL RECEPTOR Vβ-Dβ-Jβ SEQUENCE AND METHODS FOR ITS DETECTION

Publications (1)

Publication Number Publication Date
BR0008966A true BR0008966A (pt) 2002-10-15

Family

ID=22395857

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0008966-4A BR0008966A (pt) 1999-02-23 2000-02-22 Sequência vbeta-dbeta-jbeta de receptor de célula t e processos para a detecção da mesma

Country Status (16)

Country Link
US (1) US6303314B1 (pt)
EP (1) EP1159457B1 (pt)
JP (2) JP2003504005A (pt)
KR (1) KR100479648B1 (pt)
CN (1) CN1355852A (pt)
AT (1) ATE486956T1 (pt)
AU (2) AU774952B2 (pt)
BR (1) BR0008966A (pt)
CA (1) CA2362099C (pt)
DE (1) DE60045188D1 (pt)
HK (1) HK1044965A1 (pt)
HU (1) HUP0202574A2 (pt)
NZ (1) NZ513630A (pt)
PL (1) PL364917A1 (pt)
RU (1) RU2251552C2 (pt)
WO (1) WO2000050641A1 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002016434A1 (en) * 2000-08-22 2002-02-28 Baylor College Of Medicine T CELL RECEPTOR Vβ-Dβ-Jβ SEQUENCE AND METHODS FOR ITS DETECTION
US7658926B2 (en) * 2001-09-14 2010-02-09 Opexa Pharmaceuticals, Inc. Autologous T-cell vaccines materials and methods
US7744893B2 (en) * 2002-06-05 2010-06-29 Baylor College Of Medicine T cell receptor CDR3 sequences associated with multiple sclerosis and compositions comprising same
BR0311578A (pt) * 2002-06-05 2007-04-27 Baylor College Medicine seqüências de receptores cdr3 de células t e métodos para detecção
EP2363710B1 (en) * 2002-08-08 2015-07-01 Baylor College Of Medicine Isolation and identification of T cells
WO2004060145A2 (en) * 2002-12-31 2004-07-22 Baylor College Of Medicine Isolation and identification of cross-reactive t cells
ES2478446T3 (es) 2003-06-27 2014-07-22 International Institute Of Cancer Immunology, Inc. Método de selección de pacientes candidatos para la vacuna contra WT1
PL2016414T3 (pl) * 2006-05-05 2016-01-29 Opexa Therapeutics Szczepionka z komórek T
EP3173480A3 (en) 2007-03-05 2017-08-16 International Institute of Cancer Immunology, Inc. Cancer antigen-specific t-cell receptor gene, peptide encoded by the gene, and use of them
CN101903535A (zh) 2007-03-28 2010-12-01 信号诊断公司 高解析度分析核酸以检测序列变异的***和方法
US10669574B2 (en) 2008-11-18 2020-06-02 XCR Diagnostics, Inc. DNA amplification technology
US9803246B2 (en) 2011-06-28 2017-10-31 International Institute Of Cancer Immunology, Inc. Receptor gene for peptide cancer antigen-specific T cell
CN102875667B (zh) * 2012-09-05 2014-07-09 南方医科大学 一种HIV-1肽Env120-128特异性TCR、其重组逆转录病毒载体与应用
ES2925313T3 (es) 2013-10-09 2022-10-14 Fluoresentric Inc Método para la detección de secuencias de ácido nucleico diana
WO2016138500A1 (en) * 2015-02-27 2016-09-01 Cellular Research, Inc. Methods and compositions for barcoding nucleic acids for sequencing
US11319590B2 (en) * 2017-01-31 2022-05-03 Ludwig Institute For Cancer Research Ltd. Enhanced immune cell receptor sequencing methods

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3836656A1 (de) 1988-10-27 1990-05-03 Boehringer Mannheim Gmbh Neue digoxigenin-derivate und ihre verwendung
US5614192A (en) 1989-07-19 1997-03-25 Connective Therapeutics, Inc. T cell receptor peptides as therapeutics for immune-related disease
WO1993012814A2 (en) 1991-12-24 1993-07-08 The Immune Response Corporation Vaccination and methods against diseases resulting from pathogenic responses by specific t cell populations
WO1995034320A2 (en) 1994-06-07 1995-12-21 Regents Of The University Of Minnesota Methods for inhibiting antigen specific t cell responses
WO1996018105A1 (en) * 1994-12-06 1996-06-13 The President And Fellows Of Harvard College Single chain t-cell receptor

Also Published As

Publication number Publication date
RU2251552C2 (ru) 2005-05-10
KR20020013503A (ko) 2002-02-20
PL364917A1 (en) 2004-12-27
DE60045188D1 (de) 2010-12-16
CA2362099C (en) 2014-05-13
WO2000050641A1 (en) 2000-08-31
US6303314B1 (en) 2001-10-16
CA2362099A1 (en) 2000-08-31
CN1355852A (zh) 2002-06-26
AU774952B2 (en) 2004-07-15
HK1044965A1 (zh) 2002-11-08
HUP0202574A2 (en) 2002-12-28
EP1159457B1 (en) 2010-11-03
NZ513630A (en) 2001-09-28
AU2004220763A1 (en) 2004-11-11
AU4251200A (en) 2000-09-14
EP1159457A1 (en) 2001-12-05
ATE486956T1 (de) 2010-11-15
JP2003504005A (ja) 2003-02-04
EP1159457A4 (en) 2004-11-17
KR100479648B1 (ko) 2005-03-30
JP2007308502A (ja) 2007-11-29

Similar Documents

Publication Publication Date Title
BR0008966A (pt) Sequência vbeta-dbeta-jbeta de receptor de célula t e processos para a detecção da mesma
O'Connor et al. Ring-opened 7-methylguanine residues in DNA are a block to in vitro DNA synthesis
Brooks X chromosome inactivation and autoimmunity
US9981020B2 (en) Methods and compositions for RNA-guided treatment of HIV infection
Ficht et al. Single-Nucleotide-Specific PNA− Peptide Ligation on Synthetic and PCR DNA Templates
US20190032057A1 (en) Methods and compositions for rna-guided treatment of hiv infection
ES2555524T3 (es) Coadministración de un agente unido a un péptido de interiorización tat con un agente antiinflamatorio
MX9803308A (es) Metodos y composiciones para la deteccion de secuencias especificas de nucleotidos.
BR9711444A (pt) Derivados de adenosina substituìdos por heterocìclico n6.
ES2385867T1 (es) Método y kit para la cuantificación cromosómica molecular
BR0005804A (pt) Sequências de nucleotìdeos que codificam o genezwa1
Tailhades et al. Solid-phase synthesis of difficult purine-rich PNAs through selective Hmb incorporation: Application to the total synthesis of cell penetrating peptide-PNAs
Padmanabhan et al. Nucleotide sequence analysis of DNA: IV. Complete nucleotide sequence of the left-hand cohesive end of coliphage 186 DNA
BR0017319A (pt) Seq ência vbeta-dbeta-jbeta receptora de células t e métodos para sua detecção
BR0008313A (pt) Composições e métodos para ativação não-direcionada de genes endógenos
HUP9702251A2 (hu) Többfunkciós ligandumrendszer nukleinsavak sejtspecifikus bejuttatására
JP2021500016A5 (pt)
US20180251847A1 (en) Method of predicting the tumor response to dna methylation inhibitors and alternative therapeutic regimen for overcoming resistance
McMahon et al. Peptide nucleic acids specifically cause antigene effects in vivo by systemic injection
JPH10508183A (ja) Ｈｉｖ逆転写酵素により取り込まれ、そして不正確な塩基対合を引き起こすヌクレオシドアナログについてスクリーニングする方法
McMahon et al. Intraperitoneal injection of antisense peptide nucleic acids targeted to the mu receptor decreases response to morphine and receptor protein levels in rat brain
Santos-Rebouças Epigenetics of X-chromosome Inactivation
BR0307257A (pt) Polimorfismos genéticos no gene da pré-pró-taquicinina
CN106459979A (zh) 用于结合补体组分3蛋白的核酸化合物
US20230108957A1 (en) Treatment Of Psychiatric Disorders And Psychiatric Disorder-Associated MRI Phenotypes With Stabilin 1 (STAB1) Inhibitors

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements